Mixed Clinical Successes and Market Pressures Test Healthcare's Role as an AI Hedge

While strong pipeline execution and revenue growth for Eli Lilly and Merck bolster the case for healthcare as a defensive play, significant clinical trial setbacks for Novo Nordisk introduce volatility that complicates its reliability as a stable hedge against tech sell-offs.

What changed

Recent developments show a split in performance across major pharmaceutical players. Eli Lilly reported $98 million in Q2 sales for Foundayo (an oral GLP-1) and secured UK approval, expanding its market reach. Amgen reported robust growth with 22 products achieving double-digit sales and 17 products exceeding $1 billion in annual revenue. Meanwhile, Merck saw an upward revision in fair value estimates from analysts, moving toward a range of $140 to $155 (up from $132.78). Conversely, Novo Nordisk faced setbacks including the failure of its Ziltivekimab heart disease trial and a reported 4% monthly dip in stock price as the CEO acknowledged losing market share to Eli Lilly. Additionally, AbbVie reported a 12.4% increase in worldwide net revenues for Q1 2026.

Why it matters

The success of Eli Lilly’s Foundayo and Amgen's broad portfolio growth strengthens the thesis that healthcare can serve as a defensive hedge; these results indicate that despite broader market volatility, specific high-demand medical treatments provide stable revenue streams. Merck's upwardly revised fair value suggests that established pharmaceutical giants may offer more predictable returns than volatile AI-driven stocks during periods of tech sell-offs.

Opposing sources and risks

Several factors could undermine the thesis:

  • Novo Nordisk's trial failures (Ziltivekimab) and subsequent stock declines suggest that clinical outcomes can still trigger significant volatility.
  • Amgen faces potential risk from a recent data breach and an ongoing review of Tavneos.
  • Eli Lilly is currently navigating legal challenges regarding illegal retatrutide sales, which could lead to regulatory scrutiny or litigation costs.

What to watch

  • Continued regulatory approval progress for Merck's RSV vaccine.
  • Resolution of legal disputes concerning retatrutide and illicit weight-loss drug markets.
  • Further clinical trial results for Novo Nordisk’s pipeline candidates.
  • Analyst sentiment regarding the fair value and valuation of AbbVie as it navigates post-Humira growth.
  • Ongoing market share dynamics between Eli Lilly and Novo Nordisk in the GLP-1 space.

Related Arbora context

  • concept-glp1-obesity-drug-coverage
  • concept-healthcare-managed-care-aging-demographics
  • concept-pfizer-largecap-pharma-value-recovery
  • concept-abbvie-largecap-pharma-ma-pipeline-build
  • concept-pharma-china-supply-chain-decoupling-pressure

Sources

This is research notes, not financial advice.